Detalhe da pesquisa
1.
Race and ethnicity and the success of immune tolerance induction among people with severe haemophilia A in the United States.
Haemophilia
; 30(3): 628-637, 2024 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-38462837
2.
Racial and ethnic differences in reported haemophilia death rates in the United States.
Haemophilia
; 29(6): 1410-1418, 2023 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-37718571
3.
Cross-sectional study evaluating the association of haemophilia-related distress and clinically relevant outcomes.
Haemophilia
; 29(2): 505-512, 2023 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-36639952
4.
Cost-effectiveness of prophylactic emicizumab versus prophylactic recombinant factor VIII in patients with moderate or mild hemophilia A without inhibitors in the United States.
Am J Hematol
; 98(9): E247-E250, 2023 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-37401660
5.
Effect of emicizumab prophylaxis on bone and joint health markers in people with haemophilia A without factor VIII inhibitors in the HAVEN 3 study.
Haemophilia
; 28(6): 1033-1043, 2022 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-35905294
6.
Quality of life in a large multinational haemophilia B cohort (The B-Natural study) - Unmet needs remain.
Haemophilia
; 28(3): 453-461, 2022 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-35263495
7.
Emicizumab Prophylaxis in Patients Who Have Hemophilia A without Inhibitors.
N Engl J Med
; 379(9): 811-822, 2018 08 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-30157389
8.
Therapeutic plasma exchange for COVID-19-associated hyperviscosity.
Transfusion
; 61(4): 1029-1034, 2021 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-33231313
9.
Management of comorbidities in haemophilia.
Haemophilia
; 27 Suppl 3: 37-45, 2021 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-32476243
10.
An evaluation of PROMIS health domains in adults with haemophilia: A cross-sectional study.
Haemophilia
; 27(3): 375-382, 2021 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-33866654
11.
Shortening the Haemophilia Activities List (HAL) from 42 items to 18 items.
Haemophilia
; 27(6): 1062-1070, 2021 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-34498348
12.
The B-Natural study-The outcome of immune tolerance induction therapy in patients with severe haemophilia B.
Haemophilia
; 27(5): 802-813, 2021 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-34118102
13.
Outcomes for studies assessing the efficacy of hemostatic therapies in persons with congenital bleeding disorders.
Haemophilia
; 27(2): 211-220, 2021 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-33550614
14.
Validation of a new instrument to measure disease-related distress among patients with haemophilia.
Haemophilia
; 27(1): 60-68, 2021 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-33141984
15.
Development and testing of the Satisfaction Questionnaire with Intravenous or Subcutaneous Hemophilia Injection and results from the Phase 3 HAVEN 3 study of emicizumab prophylaxis in persons with haemophilia A without FVIII inhibitors.
Haemophilia
; 27(2): 221-228, 2021 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-33506955
16.
Natural history study of factor IX deficiency with focus on treatment and complications (B-Natural).
Haemophilia
; 27(1): 49-59, 2021 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-33278853
17.
Evaluating international Haemophilia Joint Health Score (HJHS) results combined with expert opinion: Options for a shorter HJHS.
Haemophilia
; 26(6): 1072-1080, 2020 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-33058441
18.
Disease-related distress among adults with haemophilia: A qualitative study.
Haemophilia
; 25(6): 988-995, 2019 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-31577383
19.
Bleeding and safety outcomes in persons with haemophilia A without inhibitors: Results from a prospective non-interventional study in a real-world setting.
Haemophilia
; 25(2): 213-220, 2019 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-30724422
20.
Factor VIII prophylaxis effects outweigh other hemostasis contributors in predicting severe haemophilia A joint outcomes.
Haemophilia
; 25(5): 867-875, 2019 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-31115111